文献速递前列腺癌

前列腺癌挽救性放疗时机的断点回归分析

Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2019-09-06

本研究纳入1992至2013年间两家三级中心1458例根治性前列腺切除术后生化复发接受挽救性放疗的患者,采用断点回归准随机设计并校正领先时间偏倚,比较早期挽救性放疗(PSA<0.5 ng/ml)与晚期挽救性放疗(PSA≥0.5 ng/ml)的转移无生存。结果显示早期挽救性放疗并未改善转移无生存。

要点

  • 断点回归设计校正领先时间偏倚后,早期挽救性放疗未改善转移无生存。
  • 5年和10年转移无生存率在PSA 0.5 ng/ml切点处差异无统计学意义。
  • Cox回归分析切点风险比为1.3(95%CI 0.8-2.4;p=0.2)。

核心结论

  • 在校正领先时间偏倚的准随机设计中,早期挽救性放疗(PSA<0.5 ng/ml)未改善转移无生存。

研究设计与样本

  • 研究纳入1992至2013年间两家三级中心1458例根治性前列腺切除术后生化复发接受挽救性放疗的前列腺癌患者。
  • 采用断点回归准随机设计并校正领先时间偏倚,比较早期挽救性放疗(PSA<0.5 ng/ml)与晚期挽救性放疗(PSA≥0.5 ng/ml)。
  • 1049例(71.9%)接受早期挽救性放疗,409例(28.1%)接受晚期挽救性放疗,平均随访84个月(IQR 52-120.4)。

主要发现

  • 5年转移无生存率在建议切点处非显著下降0.04(95%CI -0.06至0.19)。
  • 10年转移无生存率在建议切点处非显著下降0.07(95%CI -0.12至0.32)。
  • Cox回归分析显示切点风险比为1.3(95%CI 0.8-2.4;p=0.2)。

临床怎么用

  • 对于根治性前列腺切除术后生化复发患者,早期挽救性放疗(PSA<0.5 ng/ml)相较于晚期挽救性放疗未显示转移无生存获益。
  • 临床决策时应考虑缺乏早期挽救性放疗优于晚期挽救性放疗的高级别证据。

局限性

  • 本研究为观察性准随机设计,非真正随机对照试验。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a lack of randomized evidence comparing early (eSRT) to late (lSRT) salvage radiotherapy (SRT) after radical prostatectomy (RP) for prostate cancer (PCa). Moreover, the existing evidence is often affected by lead-time bias. We sought to address this gap in a cohort of 1458 PCa patients undergoing SRT for biochemical recurrence (BCR) after RP in two tertiary care centers between 1992 and 2013. Using a quasi-randomized study design known as regression discontinuity (RD) and adjusting for lead-time bias, we compared metastasis-free survival (MFS) at 5 and 10 years after surgery between eSRT (prostate-specific antigen [PSA] <0.5 ng/ml) and lSRT (PSA ≥ 0.5 ng/ml). Overall, 1049 patients (71.9%) underwent eSRT and 409 (28.1%) lSRT at a mean follow-up of 84 mo (interquartile range (IQR) 52-120.4). The MFS rate decreased nonsignificantly at the proposed cutoff by 0.04 (95% confidence interval [CI]: -0.06 to 0.19) at 5 years and by 0.07 (95% CI: - 0.12 to 0.32) at 10 years. Cox regression analysis revealed a hazard ratio for the cutoff examined of 1.3 (95% CI: 0.8-2.4; p = 0.2). In conclusion, in a quasirandomized study design accounting for lead-time bias, eSRT (PSA < 0.5 ng/ml) did not improve MFS. Our results underline the need for level-one evidence to compare eSRT and lSRT. PATIENT SUMMARY: We compared early versus late salvage radiotherapy (SRT) for biochemical recurrence after radical prostatectomy by simulating a randomized trial. We found that early SRT (initiated at prostate-specific antigen <0.5 ng/ml) compared to late SRT did not improve metastasis-free survival.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gild P, Pompe RS, Seisen T, et al. Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31501084. doi:10.1016/j.euo.2019.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。